Skip to main content
Shanghai Kehua Bio-engineering Co Ltd. logo

Shanghai Kehua Bio-engineering Co Ltd. — Investor Relations & Filings

Ticker · 002022 ISIN · CNE000001KC9 LEI · 300300MZ6ETVMSOV4A29 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,159 across all filing types
Latest filing 2026-05-13 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002022

About Shanghai Kehua Bio-engineering Co Ltd.

https://www.skhb.com/en/

Shanghai Kehua Bio-engineering Co., Ltd. (KHB) is a developer, manufacturer, and marketer of in vitro diagnostic (IVD) products. The company's core activities are centered on five key areas: immunodiagnostics, clinical chemistry, molecular diagnostics, mass spectrometry, and point-of-care testing (POCT). KHB provides a comprehensive range of diagnostic reagents and medical instruments to a diverse customer base that includes thousands of hospitals, disease control and prevention centers, and blood centers. The product portfolio encompasses various technologies, including ELISA, chemiluminescence immunoassays, and tests for infectious diseases.

Recent filings

Filing Released Lang Actions
关于产品获得医疗器械注册证的公告
Regulatory Filings Classification · 90% confidence The document is a short stock exchange announcement (under 5,000 characters) informing investors that a subsidiary received a medical device registration certificate. It contains no financial statements or management changes, nor does it attach or publish a report. It is a routine corporate/regulatory announcement and falls into the fallback category “Regulatory Filings (RNS).”
2026-05-13 Chinese
关于产品获得医疗器械注册证的公告
Regulatory Filings Classification · 88% confidence The document is an official corporate announcement regarding the award of a medical device registration certificate for a new product, providing details of the certificate and its validity. It does not contain financial statements, voting results, management changes, or offer investor guidance. It is a general regulatory disclosure that does not fit any specific report category, so it falls under the fallback “Regulatory Filings” (RNS) category.
2026-05-12 Chinese
未来三年股东分红回报规划（2026年-2028年）
Notice of Dividend Amount Classification · 95% confidence The document is a detailed plan regarding the company's shareholder dividend distribution policy for the years 2026-2028. It outlines principles, conditions, procedures, and mechanisms for profit distribution, including cash dividends and stock dividends. It is not a financial report, earnings release, or regulatory filing but a formal announcement of a dividend policy plan. This fits best under 'Notice of Dividend Amount' (DIV) category, as it relates to dividend planning and shareholder returns over a specified future period. The document length and content indicate it is a substantive policy announcement rather than a brief notice or a report publication announcement.
2026-04-16 Chinese
独立董事2025年度述职报告（郑传芳）
Board/Management Information Classification · 95% confidence The document is a detailed annual performance report of an independent director for the year 2025, describing attendance at board and committee meetings, duties performed, communication with auditors and shareholders, and overall evaluation. It is a narrative report on the director's activities and governance role rather than a financial report, earnings release, or regulatory filing. It does not contain financial statements or audit opinions but focuses on board/management information and governance practices. Therefore, it fits best under Board/Management Information (MANG). The document length is 4142 characters, which is sufficient for a detailed report but not a full annual report or audit report. No indication of it being a proxy statement, remuneration report, or other categories is present.
2026-04-16 Chinese
关于举办2025年度业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the scheduling and details of a 2025 annual performance briefing (业绩说明会) by Shanghai Kehua Bio-Engineering Co., Ltd. It references the prior disclosure of the 2025 Annual Report and its summary but does not contain the report itself or detailed financial data. The document invites investors to participate in an online earnings or performance explanation meeting. The length is short (762 characters), and the content is clearly an announcement of an event related to the annual report, not the report itself. Therefore, it fits best as an Investor Presentation (IP) announcement or a notice about an earnings briefing. Given the definitions, the closest match is Investor Presentation (IP) because it is a detailed presentation for investors focusing on financials and company strategy, which aligns with an earnings explanation meeting.
2026-04-16 Chinese
关于部分募投项目延期的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Shanghai Kehua Bio-Engineering Co., Ltd. regarding the postponement of certain fundraising investment projects. It details the use of proceeds from a convertible bond issuance, the delay in project completion dates, and the board's approval of this delay. The document references regulatory approvals and compliance with securities regulations but does not contain financial statements or detailed financial performance data. It is primarily an update on capital project timelines related to fundraising activities. The document length is 2473 characters, which is relatively short and focused on a specific capital/financing update rather than a full financial report or audit. Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2026-04-16 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.